Biorestorative Therapies, Inc. income statement BRTX

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Biorestorative Therapies, Inc. reported revenue of $359,700, down 10.3% from the year before. It recorded a net loss of $14.2 million. The operating loss came to $15.6 million, an operating margin of -4350.1%. Diluted earnings per share were -$1.58. Over the twelve months ended Mar 31, 2026, revenue was $357,870 and the net loss was $11.1 million. Across the 10 fiscal years shown, revenue grew from $36,355 in fiscal 2016 to $359,700 in fiscal 2025, about 29.0% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Mar 31, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	0 -8.5%	0 -10.3%	0 +175.0%	0 +21.7%	0 +160.4%	0 -40.3%	0 -40.8%	0 +17.1%	0 +37.0%	0 +122.8%	0 -94.2%
Cost of revenue	0	0 -15.1%	0	—	—	—	—	—	—	—	0 -100.0%
Gross profit	0	0 -9.9%	0	—	—	—	—	—	—	0 +123.4%	0 -90.1%
Research and development	9 +13.0%	10 +50.5%	7 +66.2%	4 +14.8%	4 +381.9%	1 -16.9%	1 -49.1%	2 +13.8%	2 -29.7%	2 -25.4%	3 +37.0%
Selling, general and administrative	5 +20.0%	6 +12.8%	5 -53.9%	11 -27.3%	16 -39.2%	26 +1334.2%	2 -61.2%	5 +14.5%	4 +3.1%	4 +20.3%	3 -16.1%
Operating expenses	15	16 +34.0%	12	—	—	—	—	—	—	—	—
Operating income	-14 -16.1%	-16 -35.4%	-12 +24.1%	-15 +19.8%	-19 +27.9%	-26 -855.9%	-3 +67.4%	-8 -10.3%	-8 +8.7%	-8 -7.6%	-8 -8.6%
Other non-operating income (expense)	0 +613.2%	0 -88.4%	0 -11.1%	0 +58.4%	0	—	—	—	—	—	—
Other income (expense)	3 +1911.3%	1 -45.4%	3 -46.4%	5 -16.5%	6 +132.0%	-18 -111.2%	-9 -37.1%	-6 -27.6%	-5 -355.0%	-1 -25.7%	-1 -13.0%
Pretax income	—	-14	—	—	—	—	—	—	—	-9 -9.4%	-9 -9.0%
Net income	-11 +8.6%	-14 -58.6%	-9 +13.8%	-10 +21.2%	-13 +70.2%	-44 -293.0%	-11 +23.0%	-15 -17.0%	-13 -32.5%	-9 -9.4%	-9 -9.0%
Basic EPS	-0.98 +33.7%	-1.58 -36.2%	-1.16 +53.0%	-2.47 +32.3%	-3.65	—	—	—	—	—	—
Diluted EPS	-0.98 +33.7%	-1.58 -36.2%	-1.16 +53.0%	-2.47	—	—	—	—	—	—	—
Weighted average shares, basic	11 +38.0%	9 +15.8%	8 +84.1%	4 +16.6%	4	—	—	—	—	—	—
Weighted average shares, diluted	11 +38.0%	9 +15.8%	8 +84.1%	4	—	—	—	—	—	—	—
Other measures
Depreciation and amortization	0 +6.3%	0 +11.1%	0 +14.1%	0 +37.5%	0 +35.3%	0 -26.6%	0 -44.2%	0 -9.6%	0 -7.3%	0 +0.3%	0 +20.9%
EBITDA	-14 -16.3%	-15 -35.8%	-11 +24.5%	-15 +20.1%	-19 +28.1%	-26 -896.6%	-3 +68.0%	-8 -10.9%	-7 +8.7%	-8 -7.8%	-8 -8.2%
Margins
Gross margin	92.09%	93.37%	93.00%	—	—	—	—	—	—	100.00%	99.72%
Operating margin	-3,975.00%	-4,350.05%	-2,881.59%	-10,439.49%	-15,838.08%	-57,191.03%	-3,574.12%	-6,486.16%	-6,889.78%	-10,338.62%	-21,414.04%
Pretax margin	—	-3,947.87%	—	—	—	—	—	—	—	-11,660.07%	-23,755.44%
Profit margin	-3,089.55%	-3,959.40%	-2,239.25%	-7,145.20%	-11,036.97%	-96,311.51%	-14,639.85%	-11,267.61%	-11,277.30%	-11,660.07%	-23,755.44%
EBITDA margin	-3,916.15%	-4,291.67%	-2,834.45%	-10,325.82%	-15,737.46%	-56,997.32%	-3,416.48%	-6,318.96%	-6,673.23%	-10,018.55%	-20,703.20%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Services-Misc Health & Allied Services, NEC (SIC 8090)
Listed as: BRTX (Nasdaq)
Fiscal year ends: December 31
Incorporated in: NV
Headquarters: Melville, NY
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1505497
Former names: Stem Cell Assurance, Inc. (until Aug 16, 2011)

Other Services-Misc Health & Allied Services, NEC companies

All 15 Services-Misc Health & Allied Services, NEC companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.